A Good Time to Grab Some GW Pharma

UK-based GW Pharma (GWPH) is allowing long-term investors a good entry today following the release of Q1 results and a conference call that followed.  The stock continued to retrace a good portion of its massive rally in early January today but has reversed:

Today's low was just above 70, but the stock lifted off of those levels quickly and has gotten back above the lows set near 72 last week and going into the number:

The report from the company as well as the conference call didn't really add too much new information.  GWPH will be spending aggressively this year to move along several candidates in Phase 2 or Phase 3 clinical trials, and we should expect a lot of data throughout the year.  On the call, the company suggested that it may present some data on Epidiolex, its drug under development to treat rare childhood epilepsy, at the April meeting of the American Academy of Neurology.  Furthermore, management shared anecdotal evidence that Epidiolex may not only help control seizures, but it may also help improve quality of life in these patients in other ways.  The company believes that the drug may prove helpful to patients with autism. 

The big picture summary of today's report and conference call are that there are no changes to the cash flow guidance provided in December, the company continues to advance its rich pipeline and that Epidiolex remains the key but not exclusive part of that pipeline.  The company will be sharing a significant amount of data as the year progresses on both Epidiolex as well as Sativex and other pipeline candidates.

Taking a longer-term perspective, GWPH, which at $72 is worth about $1.44 billion, has not only solid fundamentals in terms of a huge war chest ($240mm) to fund its many opportunities along ...

Read More
Comments

MJNA: It's What They Didn't Say About Kannaway That Should Make You Run Away

In typical fashion for the company, Medical Marijuana, Inc. (MJNA) dropped an aggressive press release lacking substance in what appears to be a last-ditch effort to interest investors in its comatose stock.  Before the market opened on 1/22/15, the company ...

Read More
Comments

Red Ahead for this Black Eye of the Green Rush

In a move that has been signaled by a brewing battle, Medbox (MDBX) founder and controlling shareholder Vincent Mehdizadeh moved today to replace the entire Board of Directors.  In a definitive proxy filed with the SEC, Mehdizadeh named himself, employees Matthew ...

Read More
Comments

Pot Stocks Pay Off: A Review of the Cannabis Sector

NOTE:  This is satire

What a year it was for the marijuana sector, bouncing back from a challenging 2014. While the sector ended the year well below the 2014 highs despite more than tripling in price, investors are optimistic that ...

Read More
Comments

420 Investor Interview: Paul Rosen, CEO of PharmaCan Capital

One of the most exciting themes for those looking to capitalize on the changing global cannabis industry is the rollout of Canada's Marihuana for Medical Purposes Regulations (MMPR). Health Canada, which oversees Canada’s national medical marijuana program, has issued licenses ...

Read More
Comments

Election Survey 11/03/14 - Public Survey

420 Investor conducted a survey for the public that was exactly the same as its internal survey.  The public survey, which was posted on Twitter and Facebook, consisted of six questions and was open for 50 hours, closing at 9 A.M. EDT on 11/03, ...

Read More
Comments

Stay Informed with the 420 Investor Newsletter

After a year of helping investors navigate the "Wild West" of the cannabis stock sector as 420 Investor has evolved into the leading collaborative due diligence platform, we are pleased to offer the 420 Investor Newsletter.

This monthly effort is ...

Read More
Comments

GrowBLOX "Blows" It

GrowBLOX Sciences (GBLX) posted a press release this morning. This company has spent an enormous amount of money on p.r. and investor relations and has pushed the envelope (using GoogleAds, for instance, to promote its ticker). Shockingly, the company misspelled its ...

Read More
Comments

420 Investor Interview: Tom Bollich, CEO of Surna

Surna (SRNA), based in Boulder, CO, addresses one of the key challenges facing the cannabis cultivation industry: Energy consumption. The company, which began operations this year, has technology that it has acquired that will help growers reduce one of the ...

Read More
Comments

Guest Post - Desmond Fargo: "Cen Biotech: A Promise Delivered"

The author of this article, Desmond Fargo, gave me permission to publish this piece on Creative Edge Nutrition (FITX)

The purpose of this article is to provide useful insight into Cen Biotech's recent press release regarding license, and also provide ...

Read More
Comments

Basics By Brochstein - Volume 1

This is series of nine short videos designed to help with novice education. Each video was about 8-12 minutes, with the intention of explaining key concepts in plain English, all with the goal of making you a more informed investor. ...

Read More
Comments

Interview with Paul Enright, CEO of United Cannabis (CNAB)

United Cannabis (CNAB) is a recent reverse-merger, formerly known as MySkin. The company has a relationship with Colorado-based dispensary RiverRock that will allow it to expand the brand and the intellectual property. The most recent share-structure was conveyed on April ...

Read More
Comments